Selected article for: "cell different type and different type"
Title: RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS
  • Document date: 2018_12_19
    • ID: r79h9yzz_1205
    Snippet: M. Musser Aratana Therapeutics, Inc. (co‐distributor for EP4R antagonist, Galliprant, in the U.S.) ‐ Receives research support (unrelated to Galliprant). Elanco (primary distributor for EP4R antagonist, Galliprant, in the U.S.) ‐ Receives research support (related to Galliprant but for different type of cancer, transitional cell carcinoma of the urinary bladder). C. Johannes Aratana Therapeutics, Inc. (co‐distributor for EP4R antagonist, .....
    Document: M. Musser Aratana Therapeutics, Inc. (co‐distributor for EP4R antagonist, Galliprant, in the U.S.) ‐ Receives research support (unrelated to Galliprant). Elanco (primary distributor for EP4R antagonist, Galliprant, in the U.S.) ‐ Receives research support (related to Galliprant but for different type of cancer, transitional cell carcinoma of the urinary bladder). C. Johannes Aratana Therapeutics, Inc. (co‐distributor for EP4R antagonist, Galliprant, in the U.S.) ‐ Former employee, speaking engagements, advisory board, consultant, receives honorarium, travel and research support (all unrelated to Galliprant). Elanco (primary distributor for EP4R antagonist, Galliprant, in the U.S.) ‐ Receives research support (related to Galliprant but for different type of cancer, transitional cell carcinoma of the urinary bladder).

    Search related documents:
    Co phrase search for related documents
    • cell carcinoma and transitional urinary bladder cell carcinoma: 1, 2, 3, 4, 5
    • cell carcinoma and urinary bladder: 1, 2, 3, 4, 5, 6, 7
    • cell carcinoma and urinary bladder cell carcinoma: 1, 2, 3, 4, 5
    • different type and research support: 1
    • transitional urinary bladder cell carcinoma and urinary bladder: 1, 2, 3, 4, 5, 6
    • transitional urinary bladder cell carcinoma and urinary bladder cell carcinoma: 1, 2, 3, 4, 5